Unfortunately, turning nasal vaccines into reality has a long way to go.
During last week’s FDA advisory meeting, frustration was palpable that we continue to employ a strategy that relies on chasing variants with updated boosters, ones that we know provide only a modest improvement over earlier shots, and offer a limited window of protection at that.
All of that will likely require large, complex trials — ones that might be even more expensive and take far longer to run than the ones that got us the current vaccines.
Share This Story
Author / Journalist: Lisa Jarvis | Bloomberg Opinion
BEAMSTART brings you the latest news, database, and jobs from all around the world on startups, technology, and business. Stay updated with industry news, plug-in to exciting community events, and discover incredible career opportunities with the world's most innovative companies.